INTRODUCTION {#S1}
============

We are witnessing an unprecedented time in the history of mankind, and we do not know how this will unfold in the near future. SARS-CoV-2 has taken the world by a storm and has brought down humanity to its knees. We still do not know if there will be any difference in the way different ethnicities will behave against this common enemy in the next few weeks or months. We have seen China in shambles and getting their act together of late. Italy and overall Europe is one of the worst hit. More than 400,000 have been infected all over the world,^\[[@ref1]\]^ 19,000 lives lost, we thought it may be time to look at the patterns of infection as well as mortality in different regions and see if we can notice something of relevance specific to India, and try to understand whether India will behave differently than some of the other hard hit countries to SARS-CoV-2 challenge.

WHEN DID THIS FIRST COME TO INDIA? {#S2}
==================================

The first cluster of SARS-CoV-2 was reported in China in December 2019.^\[[@ref2]\]^ India and China have a massive cross- border footfall and this is mostly small businesses visiting to buy Chinese raw material and electronic items as these are so much cheaper. Do we have enough reason to believe India may already have been exposed and many Indians may have recovered and be immune? The small increase in number of respiratory cases if any may have been barely noticeable due to the huge population and a relatively small percentage rise in people visiting emergency departments. India has a large young population, is it possible many had mild illness and recovered spontaneously. If we can understand this by widespread serological testing, we might be able to carbon date the epidemic better and will be able to understand the pace at which it is likely to spread in a more logical manner. Importantly, if at all we could do serological testing on healthcare workers who had sore throat symptoms suggestive of SARS-CoV-2 in the past 3 months, those with antibodies could be utilized as caregivers for SARS-CoV-2 patients.

THE MALARIA THEORY {#S3}
==================

We compiled a list of countries with a high prevalence of Malaria and the hardest hit countries by SARS-CoV-2.^\[[@ref3],[@ref4]\]^ Surprisingly, the countries which are hardest hit by SARS- CoV-2 have a very low incidence of Malaria (US, China, Italy, most of Europe) while those with a high incidence of Malaria have a relatively very low number of SARS-CoV-2 cases and have a lower mortality rate too. As of now, this is a hypothesis, we are not aware whether this stark difference is due to prophylaxis with chloroquine (anecdotal reports claiming activity of hydroxychloroquine and chloroquine for SARS-CoV-2),^\[[@ref5]\]^ problems in transportation and restricted mobility in parts of Africa, younger age in these countries or a immunological differences between these populations. Interestingly, zoonotic viral genome has been found inside some *Plasmodium* species, so we also speculated if these viruses are in anyway genetically related to SARS-CoV-2 and do we already have some form of immunological memory for SARS-CoV-2 in malaria endemic regions.^\[[@ref6]\]^

Statistical viewpoint {#S3_1}
---------------------

Total 107 countries' available malaria incidence (per 1000 population at risk) data (from 2000 to 2017) and number of SARS-CoV-2 cases till March 24^th^, 2020, were collected from the WHO website. We assessed the relationship between malaria incidence rate (averaged annually) and corresponding numbers of SARS-CoV-2 cases as of date. As the dispersion of numbers of SARS-CoV-2 cases was very high, we took natural log of number of SARS-CoV-2 cases to normalize the value and post that calculated the correlation between malaria incidence rate and number of SARS- CoV-2 cases. As an outcome, we found that the incidence rate of malaria and natural log of number of SARS-CoV-2 cases were significantly inversely related at 95% confidence level (*P* \< 0.0004) \[[Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\]. It clearly signifies that there is a negative correlation between number of SARS- CoV-2 cases and malaria incidence rate.

###### 

Summary statistics.

  Variable                 Observations   Min    Max        Mean      Std. deviation   Correlation coefficient   *P*-value
  ------------------------ -------------- ------ ---------- --------- ---------------- ------------------------- -----------
  Malaria incidence rate   107            0.00   511.44     95.57     137.76           **-0.33**                 0.0004
  COVID Cases              107            0.00   81748.00   1200.16   8215.49                                    
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To establish the relationship between ranking of malaria incidence rate and SARS-CoV-2 cases at nation level, we rank ordered all countries where higher rank denotes lower number. Hence, countries where malaria incidence rate is higher were ranked lower and vice versa \[[Table 2](#T2){ref-type="table"}\].

###### 

Malaria Incidence and SARS-CoV-2 disease burden- countrywise ranks

  Country                    Malaria incidence (per 1000 population at risk)   SARS-CoV-2 cases         
  -------------------------- ------------------------------------------------- ------------------ ----- ----
  Burkina Faso               511.438                                           1                  75    32
  Central African Republic   424.407                                           2                  4     65
  Equatorial Guinea          414.68                                            3                  9     56
  Oman                       0.0                                               105                66    34
  Syrian Arab Republic       0.0                                               105                1     87
  United Arab Emirates       0.0                                               105                198   22

To look graphically, we looked at average rank of countries in terms of SARS-CoV-2 disease burden with respect to countries rank for malaria incidence rate. The trendline \[[Figure 2](#F2){ref-type="fig"}\] here validates the inverse relationship between malaria incidence rate and SARS-CoV-2 disease burden, indicating that there is a possibility, malaria endemic nations are less severely impacted by SARS-CoV-2.
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Genomic similarity between the different strains of SARS- CoV-2 (2019) virus with the matryoshka RNA virus 1 (MaRNAV-1) associated with *Plasmodium vivax*^\[[@ref6]\]^ {#S3_2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

FASTA sequence of the SARS-CoV-2 virus strains isolated from different countries, namely, Wuhan USA, Italy, India, and Nepal with NCBI-IDs MT050493.1, MT066156.1, MN985325.1, NC_045512.2, MT072688.1, NC_004718.3, and KC164505.2, respectively, was retrieved from NCBI genome database. Furthermore, the FASTA genome sequence of MaRNAV-1 associated with *P. vivax* was retrieved having NCBI id MN698829.1. Further, using the blast tool from NCBI (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>), option of blastn was used to find somewhat similar sequences among the SARS-CoV-2 (30 kb) and MaRNAV-1 (3kb) viral genome.

As a result, we found that only a 15 bp long sequence actually showed alignment, with a percentage identity of 93.75%, and e-value of 3.1. The sequence starting from 22487 bp to 22502 bp of SARS-CoV-2 (NC_045512.2) virus aligned with 2796 bp to 2781 bp of MaRNAV-1 viral genome. The region which got aligned from SARS-CoV-2 codes for surface glycoprotein. The aligned region is very small too draw any conclusion as to whether these viruses share immunogenicity or not in the form of conserved domains in their surface glycoproteins, but we cannot rule out this intriguing possibility. This observation was found in all the different viral strains of SARS-CoV-2 isolated from different geographical regions.

DIFFERENCE IN LIVING CONDITIONS {#S4}
===============================

Statistics shows that the number of cases is more in developed world compared to developing nations.^\[[@ref1]\]^ The speed at which the problem has grown is again more in developed world. There is no disputing these facts. Patients with fever and respiratory distress are thronging hospitals in European and few American cities while hospitals in India are not being flooded with such cases till now. Some would blame the lower numbers tested in India and that is something we can understand only with the passage of time.

Why are there fewer cases in these nations? We have a rather simplistic view on this. One reason for high number cases in the US, Italy, and the likes could be that the citizens live mostly indoors in air-conditioned houses and offices. There may be no fresh air ventilation in homes and offices. They are forced to breathe the same air or they keep touching fomites polluted with the virus all the time. Could this be increasing transmission despite the higher population density in India? It does seem that closed surroundings may help the virus survive for much longer, as SARS-CoV-2 RNA could be detected even after up to 17 days of evacuation from cabins of diamond princess cruise ship.^\[[@ref7]\]^

Based on these facts, in addition to viral testing, quarantine, sanitizing, etc., opening windows and keeping doors open to fresh air in all the premises may be critical to reduce viral transmission. There are also data showing relation of severity of disease with higher viral load, similarly, it is possible that a higher titer exposure to the virus in a closed environment leads to adverse clinical outcome.^\[[@ref8]\]^

DOES BLOOD GROUP MATTER? {#S5}
========================

A study from China showed that A blood group was more susceptible to infection by SARS-CoV-2, while O was less susceptible.^\[[@ref9]\]^ In India, the most common blood groups are O and B while A forms about 21.5%. In China, blood Group A comprises about 28%, while in Italy it stands at 42%^\[[@ref10]\]^ could some populations be more susceptible and could there be an impact of blood group distribution on severity, needs to be examined.

DIFFERENT STRAINS IN DIFFERENT REGIONS? {#S6}
=======================================

We read with interest a study by Sardar *et al*.^\[[@ref11]\]^ which analyzed the genomic differences between the SARS-CoV-2 strain which affected China, Italy, and India. Their work has brought out notable genomic differences between these strains. Is it possible that the transmissibility, morbidity, mortality, and response to therapy depend on the particular strain? If yes, then we could have significantly different outcomes in different regions. Does that account for the different mortality rates in China, Italy, and US, or it is the advanced age and comorbidities only? If yes then we would probably need different mitigation and suppression strategies for different strains to reduce the huge economic impact of lockdown.

Will India get less severely hit due to these above differences? It is possible we feel, and we are hoping and praying we pass through this bottleneck in history safely.

Overall, we do feel that on the outside we are dealing with the worst kind of enemy, but it could very well turn out to be mankind's greatest teacher ever. It has taught us humility, brought us down on our knees. We will need to go back to our basic sciences and formulate strategies to fight this common enemy now, as well as later when it re-emerges. One thing we are optimistic about is mankind will prevail and will learn its lesson well from this historic crisis.
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